Application of the Apsara Thermal Wand System
This study has been completed.
Sponsor:
Apsara Medical Corporation
Information provided by:
Apsara Medical Corporation
ClinicalTrials.gov Identifier:
NCT00662389
First received: April 17, 2008
Last updated: July 22, 2009
Last verified: July 2009
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Results First Received: July 22, 2009
| Study Type: | Interventional |
|---|---|
| Study Design: | Allocation: Non-Randomized; Endpoint Classification: Safety Study; Intervention Model: Single Group Assignment; Masking: Open Label; Primary Purpose: Treatment |
| Condition: |
Tightening of Skin Laxity |
| Intervention: |
Device: Apsara Thermal Wand System |
Participant Flow
Recruitment Details
| Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations |
|---|
| No text entered. |
Pre-Assignment Details
| Significant events and approaches for the overall study following participant enrollment, but prior to group assignment |
|---|
| No text entered. |
Reporting Groups
| Description | |
|---|---|
| A--Thermal Wand Application | No text entered. |
Participant Flow: Overall Study
| A--Thermal Wand Application | |
|---|---|
| STARTED | 4 |
| COMPLETED | 4 |
| NOT COMPLETED | 0 |
Baseline Characteristics
Reporting Groups
| Description | |
|---|---|
| A--Thermal Wand Application | No text entered. |
Baseline Measures
| A--Thermal Wand Application | |
|---|---|
|
Number of Participants
[units: participants] |
4 |
|
Age
[units: participants] |
|
| <=18 years | 0 |
| Between 18 and 65 years | 3 |
| >=65 years | 1 |
|
Age
[units: years] Mean ± Standard Deviation |
61.7 ± 3.6 |
|
Gender
[units: participants] |
|
| Female | 4 |
| Male | 0 |
|
Region of Enrollment
[units: participants] |
|
| United States | 4 |
Outcome Measures
| 1. Primary: | Serious Adverse Events [ Time Frame: Immediate ] |
Hide Outcome Measure 1| Measure Type | Primary |
|---|---|
| Measure Title | Serious Adverse Events |
| Measure Description | Number of Serious Adverse Events |
| Time Frame | Immediate |
| Safety Issue | Yes |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| No text entered. |
Reporting Groups
| Description | |
|---|---|
| A--Thermal Wand Application | No text entered. |
Measured Values
| A--Thermal Wand Application | |
|---|---|
|
Number of Participants Analyzed
[units: participants] |
4 |
|
Serious Adverse Events
[units: Number of Serious Adverse Events] |
0 |
No statistical analysis provided for Serious Adverse Events
More Information
Certain Agreements:
Limitations and Caveats
Results Point of Contact:
No publications provided
| Principal Investigators are NOT employed by the organization sponsoring the study. | ||||||
| There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. | ||||||
The agreement is:
|
Limitations and Caveats
| Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data |
|---|
| No text entered. |
Results Point of Contact:
Name/Title: Eve Conner, Ph.D. Consultant
Organization: Apsara Medical Corporation
phone: 510 566-2495
e-mail: eaconner@sbcglobal.net
Organization: Apsara Medical Corporation
phone: 510 566-2495
e-mail: eaconner@sbcglobal.net
No publications provided
| Responsible Party: | Kim Tompkins, VP, Clinical/Regulatory/Quality |
| ClinicalTrials.gov Identifier: | NCT00662389 History of Changes |
| Other Study ID Numbers: | NEIRB08-090 |
| Study First Received: | April 17, 2008 |
| Results First Received: | July 22, 2009 |
| Last Updated: | July 22, 2009 |
| Health Authority: | United States: Institutional Review Board |